Abstract

Provided are: a polypeptide of any one of the following items (i) to (iii); an antibacterial protein comprising the polypeptide; an antibacterial agent; a disinfectant; a pharmaceutical composition; an antibacterial agent composition; and a disinfectant composition. (i) A polypeptide comprising the amino acid sequence represented by SEQ ID NO:1; (ii) a polypeptide comprising an amino acid sequence having a structure such that one or several amino acid residues are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:1; or (iii) a polypeptide comprising an amino acid sequence having sequence identity of 80% or higher with the amino acid sequence represented by SEQ ID NO:1.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A01N 63/50 - Isolated enzymesIsolated proteins
• A01P 3/00 - Fungicides
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 27/02 - Ophthalmic agents
• A61P 31/04 - Antibacterial agents
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 19/00 - Hybrid peptides
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/33 - Genes encoding viral proteins

Abstract

The purpose of the present invention is to provide a preparation capable of effectively ameliorating organ disorder. The organ disorder amelioration agent according to the present invention is characterized by containing, as an active ingredient, an H-type ulvan or an alkali metal ion salt of ulvan.

IPC Classes  ?

• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/12 - Antidiarrhoeals

Abstract

The purpose of the present invention is to provide: a novel ion complex which has excellent ability to trap fine particles and functions to inhibit pollen from rupturing; a dispersion containing the novel ion complex; and a filter for trapping fine particles, the filter including a coating layer containing the novel ion complex as an active ingredient. This ion complex is characterized by comprising an anionic polymer and a quaternary ammonium ion compound represented by formula (I). [In the formula, R1and R24-204-20 alkyl group, and R3and R41-24-204-20 alkyl group.]

IPC Classes  ?

• C08L 101/02 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups
• A01N 33/12 - Quaternary ammonium compounds
• A01N 61/00 - Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• A01P 3/00 - Fungicides
• A61L 9/16 - Disinfection, sterilisation or deodorisation of air using physical phenomena
• B01D 39/00 - Filtering material for liquid or gaseous fluids
• C08K 5/19 - Quaternary ammonium compounds
• C08L 5/04 - Alginic acidDerivatives thereof
• C08L 33/02 - Homopolymers or copolymers of acidsMetal or ammonium salts thereof
• C08L 77/04 - Polyamides derived from alpha-amino carboxylic acids

Abstract

[Problem] The purpose of the present invention is to provide: a compound that can be suitably used in a fluorescent dye or the like; a novel fluorescent dye and a kit for conveniently detecting cells; a novel method for conveniently detecting cells; and a dyeing material or the like. [Solution] A compound represented by formula (1) or a salt thereof. (In formula (1), R1 is an alkyl group having 1-12 carbon atoms, an alkenyl group having 2-12 carbon atoms, an alkynyl group having 2-12 carbon atoms, or the like, all of the foregoing being substituted or unsubstituted.)

IPC Classes  ?

• C07C 229/18 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
• C07D 295/112 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

With respect to an insertion tool to be inserted into a natural opening in a body, e.g., the vagina and rectum, the purpose of the present invention is to allow light to efficiently and safely enter a tissue in a body cavity from the distal end of the insertion tool in the state where the insertion tool has been inserted into the body, and to enable satisfactory observation of light, which enters the tissue in the body cavity from the distal end, from the abdominal cavity side. An insertion tool 1A to be inserted into a natural opening in a body is provided with a light source 10 at the proximal end of a cylindrical body 2 formed from a light-conductive resin, and is also provided with a light-emitting section at the distal end thereof. The light-emitting section located at the distal end has a structure such that light entering the proximal end is injected at high intensity from the light-emitting section located at the distal end toward the radial outside of the cylindrical body 2. An example of the light-emitting section located at the distal end is an annular convex part 20A that is convex toward the radial outside of the cylindrical body 2 and has a curved surface 21 that is closely adhered to a tissue in a body cavity.

IPC Classes  ?

• A61B 17/42 - Gynaecological or obstetrical instruments or methods
• A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure

Abstract

The present invention aims at providing a compound that can be suitably used as a fluorescent dye or the like, a novel fluorescent dye and kit for easily detecting cells, a novel method for easily detecting cells or the like, and so on. A compound represented by the following formula (1) or a salt thereof: The present invention aims at providing a compound that can be suitably used as a fluorescent dye or the like, a novel fluorescent dye and kit for easily detecting cells, a novel method for easily detecting cells or the like, and so on. A compound represented by the following formula (1) or a salt thereof: in the formula (1), R1 is a substituted or unsubstituted alkyl group having 1 to 12 carbon atoms or the like; R2 and R3 are each independently a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms or the like; R4 and R5 are each independently an alkyl group having 1 to 12 carbon atoms or the like; n is an integer of 1 to 4; and a and b are each independently an integer of 0 to 4.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C09B 3/70 - Benzo-, naphtho-, or anthra-dianthrones

Abstract

The purpose of the present invention is to provide an anti-aging agent which exhibits an excellent effect such as a mitochondria activating effect. The anti-aging agent according to the present invention is characterized by containing an H-type ulvan or an alkali metal ion salt of ulvan as an active ingredient.

IPC Classes  ?

• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
• A61P 39/06 - Free radical scavengers or antioxidants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to provide a preparation that can effectively suppress post-operative delirium. A post-operative delirium suppressant according to the present invention is characterized by containing a GABA-A receptor selective positive allosteric modulator as an active ingredient.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An eco-friendly plastic and an eco-friendly plastic fiber according to the present invention contain: a polymeric compound having low microbial decomposability; and a poly-γ-glutamic acid (PGA), or a salt thereof, contained in the polymeric compound. The PGA may be used in the form of a PGA ion complex. The PGA ion complex according to the present invention comprises a poly-γ-glutamic acid (PGA), and a polyvalent metallic ion that is trivalent or higher.

IPC Classes  ?

• C08L 67/00 - Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chainCompositions of derivatives of such polymers
• C08L 77/04 - Polyamides derived from alpha-amino carboxylic acids
• D01F 6/92 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds of polyesters

Abstract

The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61P 31/04 - Antibacterial agents
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

The present invention provides a production method of an extracellular vesicle population containing extracellular vesicles on the membrane surface of which phosphatidylserine is low expressed, said method comprising: (1) a step for culturing mesenchymal stem cells in a medium containing one or more sulfuric acid compounds selected from the group consisting of a sulfated glycolipid, cholesterol sulfate and pharmaceutically acceptable salts thereof; and (2) a step for collecting an extracellular vesicle population contained in the medium after carrying out the above step (1). The present invention also provides an extracellular vesicle population containing extracellular vesicles on the membrane surface of which phosphatidylserine is low expressed.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A living body compressing clip 100 includes a clip body 1 with metallic arm parts 5a and 5b configured to hold a living body tissue. The clip body 1 includes compressing pieces 10 that protrude from distal end parts of the arm parts 5a and 5b in a long-side direction of the arm parts 5a and 5b. The compressing pieces 10 are formed from a flexible resin and hold a fluorescent dye. According to the living body compressing clip 100, the compressing pieces 10 causes a vascular network to collapse while holding the living body tissue by the arm parts 5a and 5b. Therefore, when the arm parts 5a and 5b hold the mucosal tissue of the tubular organ and excitation light is applied thereto, the fluorescence emitted by the compressing pieces 10 can be satisfactorily confirmed from the serosal side.

IPC Classes  ?

• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord
• A61B 17/128 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord for applying or removing clamps or clips

Abstract

The purpose of the present invention is to provide an anti-lifestyle disease agent which is safer and has an anti-obesity activity, an activity of improving insulin resistance, an activity of lowering blood sugar level, an activity of lowering blood lipid level, and the like. The anti-lifestyle disease agent is characterized by containing a compound represented by Formula (I) or a salt thereof as an active ingredient.　R12222R2... (I) (In the formula, R1and R21-61-6 alkyl group.)

IPC Classes  ?

• A61K 31/225 - Polycarboxylic acids
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure provides a humanized antibody that specifically binds to Glypican-1 (GPC-1), and also provides technologies, methods, medicines, and the like related to the humanized antibody. In one aspect, the present disclosure provides a humanized anti-GPC-1 monoclonal antibody that has a high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells. In another aspect, the present disclosure also provides a composition for preventing or treating Glypican-1-positive cancer that includes a complex of a humanized anti-GPC-1 monoclonal antibody and a medicine having cytotoxic activity.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

Provided is a cranial neuropathy therapeutic agent that contains, as an active ingredient, a culture supernatant for umbilical cord blood monocytic cells.

IPC Classes  ?

• A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• A61K 38/20 - Interleukins
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided is a cranial nerve disorder therapeutic agent that includes, as an active ingredient, a culture supernatant of tissue cells derived from a fetal appendage.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

A subject S to which 17O gas has been administered is placed within a fixed uniform static magnetic field of an NMR apparatus 1. The subject is irradiated, through proton coupling, with an excitation pulse produced using a pulse sequence having a short cycle time of 20.4 msec or less, preferably 10.4 msec or less, and more preferably 5.6 msec or less. An NMR signal generated due to 17O nuclei of 17O water produced within the subject by oxygen metabolism of the 17O gas being excited by irradiation with the excitation pulse is detected with high sensitivity and is processed in accordance with a prescribed imaging sequence in which an MRS sequence is used.

IPC Classes  ?

• G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
• G01R 33/54 - Signal processing systems, e.g. using pulse sequences
• G01R 33/485 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/09 - Recombinant DNA-technology
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

Provided is a separation and purification method comprising: a step (1) for adjusting a sample solution including a first metal ion, a second metal ion, and a chelating agent to a pH at which the second metal ion chelates to form a complex having a negative charge, while the first metal ion essentially does not chelate; a step (2-1) for bringing a solution containing the first metal ion and the chelated second metal ion obtained in step (1) into contact with a cation exchange body, and adsorbing the first metal ion in the solution on the cation exchange body to remove the first metal ion; a step (2-2) for obtaining a treated solution containing the chelated second metal ion, from which the first metal ion has been removed; and a step (3) for decomposing the chelating agent for the chelated second metal ion contained in the treated solution obtained in step (2-2), to obtain a purified second metal ion. This separation and purification method is suitable when the second metal is a radioisotope obtained by conversion from the first metal.

IPC Classes  ?

• G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• B01J 39/05 - Processes using organic exchangers in the strongly acidic form
• B01J 39/07 - Processes using organic exchangers in the weakly acidic form
• B01J 39/09 - Inorganic material
• B01J 39/20 - Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 39/22 - Cellulose or woodDerivatives thereof
• B01J 47/02 - Column or bed processes
• B01J 47/14 - Controlling or regulating
• B01J 49/00 - Regeneration or reactivation of ion-exchangersApparatus therefor
• B01J 49/20 - Regeneration or reactivation of ion-exchangersApparatus therefor of membranes

Abstract

Provided is an aerial projection device that can display an image in midair by using an image display means having a simple structure. This aerial projection device 10 is configured from: a holographic projector unit 10a that emits diffracted light which is illuminated collimated light diffracted on the basis of interference information regarding a hologram of a cube which is a prescribed image; and a projection unit 10b that comprises a stereoscopic screen 28 onto which the diffracted light is illuminated such that the cube is projected thereon, a second half-silvered mirror 30 which is disposed at an angle relative to the diffracted light illuminated onto the stereoscopic screen 28 at a location illuminated by transmitted-diffused light of the diffracted light that has been transmitted through and diffused by the screen, and a retroreflective sheet 32 which is illuminated by light transmitted through the second half-silvered mirror 30, wherein a real image 34 of the cube is formed in midair by reflected light, which is obtained by the light transmitted through the second half-silvered mirror 30, of the transmitted-diffused light, being reflected by the retroreflective sheet 32, emitted in the opposite direction along the original incidence path, and reflected by the second half-silvered mirror 30.

IPC Classes  ?

• G02B 30/56 - Optical systems or apparatus for producing three-dimensional [3D] effects, e.g. stereoscopic images the image being built up from image elements distributed over a 3D volume, e.g. voxels by projecting aerial or floating images

Abstract

A novel anti-tumor agent capable of delivering siRNA or shRNA specifically to pancreatic cancer cells and suppressing tumor growth, invasion, and metastasis of pancreatic cancer is provided. The present invention provides a nucleic acid delivery enhancer for delivering siRNA or shRNA into cells, which consists of a folic acid-cationic oligopeptide complex. The present invention also provides an anti-tumor agent having siRNA or shRNA capable of binding to mRNA or snoRNA expressed in pancreatic cancer cells to inhibit its expression and a folic acid-cationic oligopeptide complex. The siRNA is capable of binding to RNA selected from the group consisting of, for example, SNORA18 snoRNA, NUP85 mRNA, WASF2 mRNA, and SNORA22 snoRNA.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61P 35/00 - Antineoplastic agents

Abstract

The purpose of the present invention is to provide: a method for producing novel β-1,3-1,6-glucan exhibiting an excellent anticancer action; novel black yeast-like bacteria used in said production method; and novel β-1,3-1,6-glucan exhibiting an excellent anticancer action. A method for producing β-1,3-1,6-glucan according to the present invention is characterized by comprising a step for culturing an Aureobasidium pullulans APNN-M163 strain (accession number: NITE BP-03377) in a culture medium.

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12N 1/14 - Fungi Culture media therefor

Abstract

The purpose of the present invention is to provide a compound that can be suitably used in a fluorochrome or similar, a novel fluorochrome and kit for conveniently detecting cells, and a novel method for conveniently detecting cells or similar.　A compound represented by formula (1) or a salt thereof. (In formula (1), R1is a substituted or unsubstituted C1-12 alkyl group or similar, R2and R3are each independently a substituted or unsubstituted C1-6 alkyl group or similar, R4and R5 are each independently a C1-12 alkyl group or similar, n is an integer from 1 to 4, and a and b are each independently an integer from 0 to 4.)

IPC Classes  ?

• C07D 295/112 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• A61K 51/04 - Organic compounds
• C09B 57/00 - Other synthetic dyes of known constitution
• C09B 67/20 - Preparations of organic pigments
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The purpose of the present invention is to provide an adhesive agent which is safe and has low environmental impact, and an adhering method which uses the adhesive agent. An adhesive agent according to the present invention is characterized by comprising, as active components, poly-γ-glutamic acid and a specific pyridinium compound. A method according to the present invention for adhering two adhesion targets is characterized by comprising: a step for either softening the adhesive agent according to the present invention on the surface of at least one of the adhesion targets, or adhering, onto the surface of at least one of the adhesion targets, the adhesive agent according to the present invention which has been softened; and a step for press-bonding, onto the softened adhesive agent on the surface of one of the adhesion targets, the other one of the adhesion targets.

IPC Classes  ?

• C08G 69/48 - Polymers modified by chemical after-treatment
• C09J 11/06 - Non-macromolecular additives organic
• C09J 189/00 - Adhesives based on proteinsAdhesives based on derivatives thereof

Abstract

Provided is a method for visualizing gaps in a sample whereby it is possible to distinguish between water and organic matter that both have a low X-ray absorption rate. The method for visualizing gaps in a sample involves the use of X-ray CT and includes a step in which an indicator obtained by filling the gaps in a sample with an ionic liquid containing a component with high X-ray absorption properties is prepared, the prepared indicator is irradiated with X-rays, X-rays that pass through the indicator are detected, and an image of the indicator in which the contrast is enhanced between gap locations and other locations is obtained.

IPC Classes  ?

• G01N 23/046 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material using tomography, e.g. computed tomography [CT]

Abstract

This living body compression clip 100 is equipped with a clip body 1 having metal arm parts 5a, 5b that pinch a living body tissue. The clip body 1 has compression pieces 10 that protrude from the distal end sections of the arm parts 5a, 5b in the longitudinal direction of the arm parts 5a, 5b. The compression pieces 10 are formed from a flexible resin and hold a fluorescent dye. According to this living body compression clip 100, the compression pieces 10 collapse the vascular network while the arm parts 5a, 5b pinch the living body tissue. Therefore, when the mucosal tissue of a hollow organ is pinched by the arm parts 5a, 5b and irradiated with excitation light, the fluorescence emitted by the compression pieces 10 can be confirmed successfully from the serosa side.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord

Abstract

An endoscope includes a scope and an image capturing unit accommodated inside the scope. The image capturing unit includes: first and second prisms; a reflection film provided between oblique faces of the first and second prisms; a first trimming filter on which visible light transmitted through the first prism is incident on the first trimming filter via the reflection film; a first image sensor facing the first trimming filter; a second trimming filter on which near-infrared light transmitted through the second prism being incident on the second trimming filter via the reflection film; and a second image sensor facing the second trimming filter. The first prism is fixed to the second prism, the first trimming filter is fixed to the first prism, and the second trimming filter is fixed to the second prism.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
• H04N 5/238 - Circuitry for compensating for variation in the brightness of the object by influencing optical part of the camera
• G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
• H04N 5/225 - Television cameras

Abstract

An openable and closable clip for medical use includes a resin clip body, and a fastening ring to be fitted onto the clip body. Clip body includes a pair of opposing arm parts, and connecting part that connects base ends of respective arm parts. Each arm part includes curved part on a base end side, holding part on distal end side, and intermediate part between curved and holding parts. Curved part is curved in arc shape, and intermediate part has a thickness greater than that of curved part. Clip body closes in state where fastening ring is fitted onto clip body on side closer to connecting part than curved part, opens when fastening ring slides onto curved part from connecting part, and closes when fastening ring slides onto intermediate part from curved part. Openable and closable clip can be used in endoscope clip device and opens and closes stably.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The present invention relates to providing a new method for easily detecting tumor cells in tissue from a living body. The present invention includes a fluorescent dye containing a compound that exhibits solvatochromism for detecting tumor cells in tissue. The present invention also includes a method for staining tissue derived from a living body or applying to a living body the fluorescent dye to detect tumor cells or specify the range of tumor removal.

IPC Classes  ?

• C09K 9/02 - Organic tenebrescent materials
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C07D 295/112 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C09B 57/00 - Other synthetic dyes of known constitution
• C09B 67/20 - Preparations of organic pigments
• A61K 51/04 - Organic compounds
• G01N 1/30 - StainingImpregnating
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention relates to providing a novel method for easily detecting tumor cells in a tissue derived from an organism. The present invention includes a fluorescent dye for detecting tumor cells in a tissue, including a compound that exhibits solvatochromism. The present invention also includes a method for detecting tumor cells or specifying a tumor removal area, including applying the fluorescent dye to staining of a tissue derived from an organism and to an organism.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07D 295/112 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C09B 57/00 - Other synthetic dyes of known constitution
• C09B 67/20 - Preparations of organic pigments
• C09K 9/02 - Organic tenebrescent materials
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 1/30 - StainingImpregnating
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

A medical tool for fingertip of the present invention has a resin layer that emits red fluorescence or near-infrared fluorescence, and is used by putting it on a fingertip. More specifically, the medical tools for fingertip 1A to 1E have a finger cot shape and an opening portion 2 from which the ball of the finger is exposed when put on, and are formed of a resin that emits red fluorescence or near-infrared fluorescence. Alternatively, the medical tools for fingertip 1F and 1G have a glove shape, and a printing layer 8, 9 that is formed of a resin that emits red fluorescence or near-infrared fluorescence on or around the ball of the finger thereof. Further alternatively, the medical tools for fingertip 1H and 1I are a sticker-like medical tool having an adhesive layer provided to one surface of the resin layer that emits red fluorescence or near-infrared fluorescence, and have a size that allows it to be attached to the ball of the finger. When the medical tools for fingertip are put on the tip of a finger of a surgeon used for palpation of a living body, the position of an affected site which has been specified from the mucosal side by the palpation can be accurately specified from the serosal side.

IPC Classes  ?

• A61B 42/20 - Finger-stalls specially adapted for surgery
• A41D 19/00 - Gloves
• A41D 19/015 - Protective gloves
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure

Abstract

Provided is a culture medium suitable for the production of a nerve regeneration promoting substance by a tissue cell derived from a fetal appendage and/or a cord blood cell.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/0786 - MonocytesMacrophages
• C12N 5/0789 - Stem cellsMultipotent progenitor cells

Abstract

Provided is a cranial nerve disorder therapeutic agent that includes, as an active ingredient, a culture supernatant of tissue cells derived from a fetal appendage.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
• A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/20 - Interleukins
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/20 - HypnoticsSedatives
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 39/02 - Antidotes
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a cranial neuropathy therapeutic agent that contains, as an active ingredient, a culture supernatant for umbilical cord blood monocytic cells.

IPC Classes  ?

• A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/20 - Interleukins
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present disclosure provides a humanized antibody specifically binding to glypican-1 (GPC-1) and a technique, a method, a drug, etc., each related thereto. In one aspect, the present disclosure provides a humanized anti-GPC-1 monoclonal antibody that has high affinity to GPC-1 and exhibits high internalization activity in GPC-1 positive cells. In another aspect, the present disclosure provides a composition for preventing or treating glypican-1-positive cancer, said composition comprising a complex of the humanized anti-GPC-1 monoclonal antibody with a drug having cytotoxic activity.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/46 - Hybrid immunoglobulins
• C12N 15/13 - Immunoglobulins

Abstract

The present disclosure provides a composition for treating a type of cancer which has CAFs (e.g., a refractory tumor). In one aspect, the present disclosure provides a composition for treating a type of cancer which has cancer-associated fibroblasts (CAFs), the composition comprising a complex of an anti-GPC-1 antibody or an antigen-binding fragment thereof and a drug having a cytotoxic activity. In some embodiments, the type of cancer which can be treated with the composition according to the present disclosure may have stromas. In some embodiments, the composition according to the present disclosure may treat a type of cancer which has a stroma content of at least about 30%.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The purpose of the present invention is to provide a mouse model for pancreatic cancer similar to human pancreatic cancer. Specifically, the present invention pertains to a human pancreatic cancer mouse model which carries a pancreatic cancer organoid containing a human pancreatic cancer cell line S2-130.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/09 - Tumour cells
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

A specimen S to which 17O gas has been administered is placed within a fixed uniform static magnetic field of an NMR apparatus 1. The sample is irradiated, through proton coupling, with an excitation pulse produced using a pulse sequence having a short cycle time of 20.4 msec or less, preferably 10.4 msec or less, and more preferably 5.6 msec or less. An NMR signal generated due to 17O nuclei of 17O water produced within the specimen by oxygen metabolism of the 17O gas being excited by irradiation with the excitation pulse is detected with high sensitivity and is processed in accordance with a prescribed imaging sequence in which an MRS sequence is used.

IPC Classes  ?

• G01R 33/485 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information
• G01N 24/00 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
• G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

Provided is a novel anti-tumor agent capable of delivering siRNA or shRNA specifically to pancreatic cancer cells and suppressing tumor enlargement, infiltration, and metastasis of pancreatic cancer.　The present invention provides a nucleic acid delivery enhancer that is for delivering siRNA or shRNA into cells and that comprises a folate-cationic oligopeptide complex. The present invention also provides an anti-tumor agent that contains a folate-cationic oligopeptide complex and siRNA or shRNA capable of binding to mRNA or snoRNA expressed in pancreatic cancer cells to inhibit the expression. Said siRNA is capable of binding to RNA selected from the group consisting of, for example, SNORA18 snoRNA, NUP85 mRNA, WASF2 mRNA, and SNORA22 snoRNA.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention addresses the problem of more rapidly predicting the three-dimensional structure of a peptide of interest.　The problem is solved by a method for predicting the nuclear magnetic resonance chemical shift values of peptides, the method comprising a step for clustering the occurrence frequency distribution of the main chain dihedral angle values (represented by φ and ψ) of the individual amino acid residues constituting a peptide of interest, to acquire a plurality of cluster distributions; a step for calculating, using a score function, the degree of similarity between each acquired cluster distribution and reference main chain dihedral angle values registered in an amino acid tripeptide database; and a step for predicting, from the calculated degree of similarity, the nuclear magnetic resonance chemical shift values of the peptide of interest.

IPC Classes  ?

• G01N 23/20 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using diffraction of the radiation by the materials, e.g. for investigating crystal structureInvestigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materialsInvestigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using reflection of the radiation by the materials
• G01N 24/00 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects

Abstract

The purpose of the present invention is to provide: a method by which the luminous intensity of a fluorescent dye is able to be enhanced even with use of light having a peak wavelength other than the maximum absorption wavelength; and a method for detecting cancer tissues, wherein the above-described method is applied. A method for enhancing the luminous intensity of a fluorescent dye according to the present invention is characterized by comprising: a step for mixing a fluorescent dye (I) with an O/W emulsion that contains, in oil droplets, at least a fat-soluble compound having a functional group that causes a bio-orthogonal reaction with the fluorescent dye (I) and a fluorescent dye (II) having a maximum absorption wavelength that is different from the maximum absorption wavelength of the fluorescent dye (I) and a maximum fluorescence wavelength that is within the absorption wavelength range of the fluorescent dye (I); and a step for irradiating the mixture of the fluorescent dye (I) and the O/W emulsion with excitation light of the fluorescent dye (II).

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• A61K 49/00 - Preparations for testing in vivo

Abstract

An openable and closable clip 1A for medical use which comprises a resin clip body 10 and a fastening ring 2 which fits onto the clip body 10, wherein the clip body 10 includes a pair of opposing arm parts 11 and a connecting part 12 that connects base ends of the arm parts 11, and each arm part 11 has a curved part 14 on a base end side, a holding part 15 on a distal end side, and an intermediate part 16 between the curved part 14 and the holding part 15. The curved part 14 is curved in an arc shape, and the intermediate part 16 has a thickness greater than the thickness of the curved part 14. The clip body 10 closes in a state in which the fastening ring 2 is fitted onto the clip body 10 on the connecting part 12 side of the curved part 14, opens in a state in which the fastening ring 2 is slid onto the curved part 14 from the connecting part 12, and closes in a state in which the fastening ring 2 is slid onto the intermediate part 16 from the curved part 14. The openable and closable clip 1A can be used in an endoscope clip device and opens and closes stably.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord

Abstract

The method for diagnosing cerebrospinal fluid hypovolemia includes injecting saline into a subdural space of a subject in a decubitus position, raising an upper body of the subject, and then determining whether the subject has headache or not, or headache of the subject is relieved or not.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Abstract

An object of the present invention is to provide a resin composition which can be detected both by X-ray radiation and by fluorescence or phosphorescence, and a molded article obtained from the resin composition. The present invention provides a resin composition containing a light-emitting substance and a radiopaque substance; in which the light-emitting substance is a near-infrared fluorescent material or a phosphorescent material. a radiopaque substance of the resin composition is any one of barium sulfate, bismuth oxide, bismuth subcarbonate, calcium carbonate, aluminum hydroxide, tungsten, zinc oxide, zirconium oxide, zirconium, titanium, platinum, bismuth subnitrate, and bismuth. A molded article can be obtained by processing any one of the resin compositions described above.

IPC Classes  ?

• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 21/64 - FluorescencePhosphorescence
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/12 - Arrangements for detecting or locating foreign bodies
• C08K 3/013 - Fillers, pigments or reinforcing additives
• A61L 31/18 - Materials at least partially X-ray or laser opaque
• A61L 29/14 - Materials characterised by their function or physical properties
• A61L 29/18 - Materials at least partially X-ray or laser opaque
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 31/14 - Materials characterised by their function or physical properties
• C08K 5/55 - Boron-containing compounds
• G07D 7/005 - Testing security markings invisible to the naked eye, e.g. verifying thickened lines or unobtrusive markings or alterations

Abstract

This medical tool for a fingertip comprises a resin layer that emits red fluorescence or near infrared fluorescence, and is to be worn on a fingertip. More specifically, the medical tool for a fingertip 1A to 1E has a finger cot shape, has an open window portion 2 from which the finger pad is exposed when worn on a finger, and is formed of a resin that emits red fluorescence or near infrared fluorescence. Alternatively, the medical tool for a fingertip 1F, 1G has a glove shape and has a print layer 8, 9 on the finger pad thereof or around the finger pad thereof, the print layer being formed of a resin that emits red fluorescence or near infrared fluorescence. Alternatively, the medical tool for a fingertip 1H, 1I is like a sticker that has an adhesive layer on one surface of a resin layer that emits red fluorescence or near infrared fluorescence, and is sized so as to be affixed within the finger pad. When an operator who performs palpation in a living body wears this medical tool for a fingertip on a fingertip, the location of a lesion identified from a mucosal side by palpation can be accurately identified from a serosal side.

IPC Classes  ?

• A61B 42/10 - Surgical gloves
• A61B 42/20 - Finger-stalls specially adapted for surgery
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The present invention provides a wastewater treatment apparatus that can treat wastewater in a stable manner, and a wastewater treatment method. A wastewater treatment facility 10 is provided with an FO membrane unit 21. The FO membrane unit 21 is immersed in a sea. The FO membrane unit 21 is provided with an FO membrane 31 and a base member 32 for attaching the FO membrane 31 and has an internal space 35 formed by the FO membrane 31 and the base member 32. The wastewater to be treated is fed into the internal space 35.

IPC Classes  ?

• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• B01D 63/00 - Apparatus in general for separation processes using semi-permeable membranes
• B01D 65/02 - Membrane cleaning or sterilisation
• C02F 3/28 - Anaerobic digestion processes
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

[ABSTRACT] Provided are a wastewater treatment apparatus and a wastewater treatment method, whereby it becomes possible to achieve the satisfactory concentration of wastewater.　A wastewater treatment apparatus 10 is equipped with a treatment tank 12 in which wastewater of interest is concentrated, a treatment tank 13 in which the wastewater concentrated in the treatment tank 12 is further concentrated, an FO membrane unit 14 which is arranged in the treatment tank 12 and is so configured as to have an internal space S formed by an FO membrane supporting material and an FO membrane 14a, an FO membrane unit 15 which is arranged in the treatment tank 13 and is so configured as to have an internal space T formed by an FO membrane supporting material and an FO membrane 15a, a driving solution circulating facility 18 for circulating a driving solution DS to be fed to the internal space S in the FO membrane unit 14 between the driving solution circulating facility 18 and the FO membrane unit 14, and a driving solution circulating facility 17 for circulating a driving solution DS to be fed to the internal space T in the FO membrane unit 15 between the driving solution circulating facility 17 and the FO membrane unit 15, wherein the driving solution DS to be used in the treatment tank 12 is composed of the driving solution DS used in the treatment tank 13 for the purpose of further concentrating the wastewater concentrated in the treatment tank 12 and water contained in the wastewater of interest moved into the driving solution DS through the FO membrane 15a.

IPC Classes  ?

• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• B01D 61/58 - Multistep processes
• C02F 3/28 - Anaerobic digestion processes
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

a carrying to outside hydrogen-containing electrolyzed water generated by electrolysis in the first electrode chamber Da; and a charge amount adjuster 10 for adjusting, during the electrolysis, an amount of electrical charge to be provided to the hydrogen-containing electrolyzed water. The charge amount adjuster 10 adjusts the amount of electrical charge per unit quantity of the generated hydrogen-containing electrolyzed water through control of an electrolytic current or an electrolytic voltage.

IPC Classes  ?

• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C02F 1/46 - Treatment of water, waste water, or sewage by electrochemical methods
• A01G 31/00 - Soilless cultivation, e.g. hydroponics

Abstract

Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder
• A61K 31/295 - Iron group metal compounds

Abstract

An analysis apparatus (100) includes an image acquisition unit (110) and an analysis unit (120). The image acquisition unit (110) acquires image data of a microfossil in a sample collected from a stratum. The analysis unit (120) analyzes the image data acquired by the image acquisition unit (110) using a machine learning result to analyze a taxon or kind of the microfossil in the image data.

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G01N 33/24 - Earth materials
• G01N 21/84 - Systems specially adapted for particular applications
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts

Abstract

This diagnosis support device (3), which supports a diagnosis of a vascular disease, includes: an image acquisition unit (341) which acquires an image including a cross section of a blood vessel; a line segment setting unit (342) which sets one or more line segments crossing the cross section; and a luminance distribution calculation unit (343) which calculates a luminance distribution on the line segment.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

The problem addressed by the present invention is to provide a technique for producing seaweed easily and efficiently. The problem is solved by a method for producing seaweed cells that includes a step for culturing under stirred conditions at least one selected from the group consisting of seaweed spores, single cells derived from the spores, and a cell mass of the spores and/or the single cells in a medium 1 substantially free of seaweed morphogens.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• A01G 33/00 - Cultivation of seaweed
• A01H 13/00 - Algae

Abstract

The objective of the present invention is to separate a metal RI in a short time. A separating device 3 for separating a radioisotope (RI) from a first solution containing a metal and the RI, obtained by transformation of the metal, is provided with an electrode 31 for applying a prescribed voltage to the first solution, wherein the prescribed voltage is a voltage with which a rate of electrodeposition of the metal onto the electrode 31 is different from the rate of electrodeposition of the RI onto the electrode 31.

IPC Classes  ?

• G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
• B01D 59/38 - Separation by electrochemical methods
• C22B 15/00 - Obtaining copper
• C22B 15/14 - Refining

Abstract

The present invention addresses the problem of providing a fish rearing feed having an excellent effect to prevent infectious diseases. A fish rearing feed which contains a water-soluble polysaccharide that does not have a substituent other than a hydroxy group in an amount of 4% by weight or less. A fish rearing feed which contains cellulose acetate having an acetyl total substitution degree of 0.4 to 1.4 inclusive.

IPC Classes  ?

• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A01K 61/13 - Prevention or treatment of fish diseases
• A23K 20/163 - SugarsPolysaccharides

Abstract

(Problem) To provide an intestinal flora-improving health food that improves intestinal flora by increasing and activating equol-producing bacteria via containing a bittern. (Solution) This intestinal flora-improving health food is characterized in that: per 100 g of the health food, the content of magnesium is 2500-6000 mg, and the content of calcium is 500-2000 mg; the ratio of magnesium content to calcium content is 2-7; the health food has a hardness of 144000-383000 mg/L; and a bittern is contained in an amount of 0.8-1.5 wt% with respect to the total weight of the health food.

IPC Classes  ?

• A23L 33/16 - Inorganic salts, minerals or trace elements
• A23L 11/00 - Pulses, i.e. fruits of leguminous plants, for production of foodProducts from legumesPreparation or treatment thereof
• A23L 11/20 - Malt products; Fermented malt products
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 35/08 - Mineral watersSeawater
• A61P 1/12 - Antidiarrhoeals
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to provide a novel bacteriophage effective for the treatment of bacterial endophthalmitis and a treatment agent for bacterial endophthalmitis that contains this novel bacteriophage. The bacterial endophthalmitis treatment agent according to the present invention is characterized by containing at least one bacteriophage selected from the group indispensably consisting of Myoviridae Spounavirinae phiEF7H (Accession No.: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (Accession No.: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (Accession No.: NITE BP-02888), and mutants thereof.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 27/02 - Ophthalmic agents
• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The purpose of the present invention is to provide a medicine for effectively protecting brain tissues from inflammatory reactions induced by cerebral ischemia. The brain protective agent according to the present invention is characterized by comprising a specific carotenoid compound as an active ingredient.

IPC Classes  ?

• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 31/365 - Lactones
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention addresses the problem of providing a compound that is a pigment capable of staining cells, is water-soluble, shows a high light emission efficiency, translocates from mitochondria to nucleus depending on mitochondrial membrane potential and exhibits light emission in the red color region. The compound according to the present invention is expressed by formula (1) [in formula (1): X is represented by formula (2) (in formula (2), R1represents a C1-C10 alkyl group, and Z-represents a counter anion to a pyridinium cation); k and m are an integer of 0-3 and l and n are an integer of 0-2, provided that k, l, m and n do not simultaneously represent 0; X's may be the same or different; R2represents an electron-donating group or an electron-withdrawing group; a and c are an integer of 0-3 and b and d are an integer of 0-2; R2's may be either the same or different and attached to a carbon atom which is not substituted by X; and the wavy line represents a geometric isomer E or Z].

IPC Classes  ?

• C09B 23/14 - Styryl dyes
• C07D 213/53 - Nitrogen atoms
• C09B 67/44 - Solutions
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour

Abstract

An object of the present invention is to provide a system for monitoring a cardiac condition of a fish wherein the system comprises: a container and a processor, wherein the container is provided with a plurality of detectors on an inner wall surface of said container, and has a space where the fish can swim on an opposite side from said detectors side as viewed from the fish in said container, the processor includes: an acquisition section that acquires photoelectric pulse waves in a plurality of areas of the fish under signal synchronization in time sequence for a specified detection period via measurement equipment having the detectors; and an extraction section that extracts a portion reflecting the photoelectric pulse wave in a heart area of the fish the most from the photoelectric pulse waves in the areas that are acquired in the detection period.

IPC Classes  ?

• A01K 61/13 - Prevention or treatment of fish diseases

Abstract

The present invention addresses the problem of providing a system for monitoring the heart condition a target fish in a state equivalent to a natural state. This problem is solved by a system for monitoring the heart condition of fish that is provided with a container and a processing device, wherein the container includes a plurality of detectors on the inner wall surface of the container and a space in which fish can swim on the side opposite to the detector side, with respect to the fish in the container, and the processing device includes an acquisition unit that acquires, in a time series, photoelectric pulse waves of a plurality of parts of the fish over a predetermined detection period under signal synchronization through a measurement device having the plurality of detectors, and an extracting unit that extracts a portion that most reflects the photoelectric pulse wave of the heart part of the fish from the photoelectric pulse waves of the plurality of parts acquired during the detection period.

IPC Classes  ?

• A01K 61/13 - Prevention or treatment of fish diseases

Abstract

The present invention addresses the problem of providing a cancer marker that has high sensitivity and specificity and can predict the "prognosis" of a pancreatic cancer patient. A marker for prognosis of pancreatic cancer according to the present invention is characterized by containing a combination of protein ITGB1 and protein PODXL and/or protein BCL7B. The present disclosure includes: a kit for diagnosing the prognosis of pancreatic cancer, characterized by comprising an antibody directed against protein ITGB1 and an antibody directed against protein PODXL and/or an antibody directed against protein BCL7B; and a method for predicting the prognosis of pancreatic cancer, characterized by comprising a step of measuring the immunohistochemistry score of each of protein ITGB1 and at least one protein selected from the group consisting of protein PODXL and protein BCL7B in a sample or the concentration of each of protein ITGB1 and at least one protein selected from the group consisting of protein PODXL and protein BCL7B in the sample.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/09 - Recombinant DNA-technology
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

[Problem] Various side effects have been reported for conventional therapeutic drugs for hyperactive bladder, and a prophylactic or therapeutic agent for hyperactive bladder without causing side effects is desired. [Solution] Provided is a prophylactic or therapeutic agent for hyperactive bladder, said agent containing 5-aminolevulinic acids (ALA) as an active ingredient.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/295 - Iron group metal compounds
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An analysis device (100) is provided with an image acquisition unit (110) and an analysis unit (120). The image acquisition unit (110) acquires image data of a microfossil in a sample obtained from a stratum. The analysis unit (120) analyzes, using machine learning results, image data acquired by the image acquisition unit (110), and thereby analyzes the taxon or category of the microfossil in the image data.

IPC Classes  ?

• G01V 8/02 - Prospecting
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

Provided is a novel anti-Glypican-1 antibody and a method for using the same. Provided is an anti-Glypican-1 antibody having an intracellular migration activity which has never been observed in conventional anti-Glypican-1 antibodies. By taking advantage of the intracellular migration activity of the antibody according to the present invention, the present invention is usable for various therapeutic purposes beyond the scope of the conventional assumption. Also provided is a composition for preventing or treating Glypican-1 positive cancer, said composition comprising a complex of a substance capable of binding to Glypican-1 (for example, an anti-Glypican-1 antibody) with a drug having a cytotoxic activity.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A01H 1/00 - Processes for modifying genotypes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• C07K 16/46 - Hybrid immunoglobulins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies

Abstract

The present invention addresses the problem of providing a feed which contributes to the improvement of the growth of aquatic animals. The present invention also addresses the problem of providing a feed by which the onset of disease injury can be suppressed during rearing or culturing aquatic animals. A feed comprising a nucleic acid such as RNA is prepared and fed for various purposes, for example, increasing feed intake, increasing feed conversion efficiency and improving biophylactic function.

IPC Classes  ?

• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A23K 20/153 - Nucleic acidsHydrolysis products or derivatives thereof
• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

a connected to the first electrode chamber Da, and dispensing out of the first electrode chamber Da electrolyzed hydrogen water generated by electrolysis in the first electrode chamber Da; and a charge amount adjuster 10 connected to the electrolysis tank D to adjust an amount of electrical charge to be provided to the electrolyzed hydrogen water. The charge amount adjuster 10 adjusts, based on a flow rate of the raw water, the amount of the electrical charge per unit quantity of the generated electrolyzed hydrogen water through control of an electrolytic current or an electrolytic voltage, so that the adjusted amount of the electrical charge is constant.

IPC Classes  ?

• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C02F 1/00 - Treatment of water, waste water, or sewage
• C02F 103/02 - Non-contaminated water, e.g. for industrial water supply

Abstract

The purpose of the present invention is to provide a magnetic resonance device having new element technology which detects a magnetic resonance signal with a high sensitivity. The magnetic resonance device is provided with: a magnetic field generating unit 1 which generates a magnetic field to be applied to a sample S; an excitation high frequency generating unit 2 which generates an excitation high frequency; a transmission coil 31 which irradiates the sample S disposed in the magnetic field, with the excitation high frequency; a reception coil 41 which receives a magnetic resonance signal generated by the sample S excited by the excitation high frequency; an electrical-to-mechanical transducer 42 which transforms a voltage of the magnetic resonance signal to a vibration of a capacity coupling film M; and a vibration measuring unit 5 which measures the vibration of the film M on the basis of optical interference.

IPC Classes  ?

• G01R 33/34 - Constructional details, e.g. resonators
• G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
• G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver

Abstract

The objective of the present invention to provide a method for accurately and safely specifying a leakage part of cerebrospinal fluid in a cerebrospinal fluid hypovolemia patient, and a method for effectively treating cerebrospinal fluid hypovolemia with utilizing the specifying method. The method for specifying a leakage part of cerebrospinal fluid in a cerebrospinal fluid hypovolemia patient according to the present invention is characterized in comprising the steps of injecting saline into a bone-marrow space of a spine of the cerebrospinal fluid hypovolemia patient, and detecting the cerebrospinal fluid or the injected saline leaked from a dura mater of the spine to specify the leakage part of the cerebrospinal fluid.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61K 49/00 - Preparations for testing in vivo
• A61K 35/14 - BloodArtificial blood

Abstract

The purpose of the present invention is to provide a marker that indicates pancreatic cancer and intraductal papillary mucinous tumors, with high sensitivity and specificity. Furthermore, the purpose of the present invention is also to provide a diagnostic kit for pancreatic cancer and intraductal papillary mucinous tumors, which detects this marker, and a method for evaluating metastatic pancreatic cancer and intraductal papillary mucinous tumors, using the marker. This marker of pancreatic cancer and intraductal papillary mucinous tumors is characterized by including one or more proteins, selected from the group consisting of secretoglobin family-1D member 2, and podocalyxin-like protein. Furthermore, this diagnostic kit for pancreatic cancer and intraductal papillary mucinous tumors is characterized by including an antibody for one or more proteins selected from the group consisting of secretoglobin family-1D member 2, and podocalyxin-like protein.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/09 - Recombinant DNA-technology
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

According to the present disclosure there are provided compositions and methods for treating malignant tumors, including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody that comprises the presently disclosed antibody heavy and light chain complementarity determining region (CDR) sequences, or an antigen-binding fragment thereof, or a functional equivalent thereof. Further provided for treating an LSR-positive malignancy is an LSR antagonist or an LSR inhibitor such as a nucleic acid. Therapeutic administration of the anti-LSR antibody to a subject having an LSR-positive malignant tumor is also described.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

An electrolyzed water-generating apparatus 1 is provided with: a first electrode chamber Da with a negative electrode 6a; a first water entry passage 4a connected to the first electrode chamber Da for supplying raw water to the first electrode chamber Da from the outside; a first water extraction passage 7a connected to the first electrode chamber Da for extracting electrolyzed hydrogen water generated in the first electrode chamber Da by electrolysis to the outside; and an electric charge-adjusting device (10) connected to the electrolysis tank D for adjusting the electric charge to be imparted to the electrolyzed hydrogen water when performing electrolysis. The electric charge-adjusting device 10 is characterized in adjusting electric charge by controlling the electrolysis current or electrolysis voltage on the basis of the flow of raw water so that the charge per unit volume of electrolyzed hydrogen water extracted is constant.

IPC Classes  ?

• C02F 1/46 - Treatment of water, waste water, or sewage by electrochemical methods

Abstract

Provided is a resin composition that has a maximum fluorescent wavelength of at least 650 nm and contains a resin and a near-infrared fluorescent pigment comprising at least one compound selected from the group consisting of compounds represented by general formulas (I1), (I2). (In the formulas, Rh and Ri, as well as Rj and Rk, form an aromatic 5-membered ring, an aromatic 6-membered ring, or a condensed aromatic ring together with the nitrogen atoms to which Rh, Ri, Rj, and Rk are bonded; each of Rl, Rm, Rn, and Ro independently represents a halogen atom, a C1-20 alkyl group, a C1-20 alkoxy group, an aryl group, or a heteroaryl group; Rr and Rs represent a hydrogen atom or an electron-withdrawing group; and each of Rp and Rq independently represents a hydrogen atom, a halogen atom, a C1-20 alkyl group, a C1-20 alkoxy group, an aryl group, or a heteroaryl group.)

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08K 5/55 - Boron-containing compounds

Abstract

Provided is a resin composition characterized by containing a resin, a light-emitting substance, and a radiopaque substance, wherein the content of the radiopaque substance is 2 mass% to 80 mass%. Also provided is any of the abovementioned resin compositions wherein the content of the light-emitting substance is 0.001 mass% to 0.5 mass%. Also provided is any of the abovementioned resin compositions wherein the light-emitting substance is a near-infrared fluorescent material or a phosphorescent material. Also provided is any of the abovementioned resin compositions wherein the radiopaque substance is barium sulfate, bismuth oxide, bismuth subcarbonate, calcium carbonate, aluminum hydroxide, tungsten, zinc oxide, zirconium oxide, zirconium, titanium, platinum, bismuth subnitrate, or bismuth. Also provided is a molded body obtained by processing any of the abovementioned resin compositions.

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• A61L 29/00 - Materials for catheters or for coating catheters
• A61L 31/00 - Materials for other surgical articles
• C08K 3/00 - Use of inorganic substances as compounding ingredients
• C08K 5/55 - Boron-containing compounds
• C09B 57/10 - Metal complexes of organic compounds not being dyes in uncomplexed form
• C09B 67/20 - Preparations of organic pigments
• C09B 67/44 - Solutions
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

An electrolyzed water-generating apparatus (1) is provided with: an electrolysis tank (D) equipped therein with a first electrode chamber (Da) with a cathode (6a), a second electrode chamber (Db) with an anode (6b), and a septum (Sp) for partitioning the first electrode chamber (Da) from the second electrode chamber (Db); a first inlet water path (4a), which is connected to the first electrode chamber (Da) and is for supplying raw water to the first electrode chamber (Da) from the outside; a first extraction water path (7a), which is connected to the first electrode chamber (Da) and is for extracting electrolyzed hydrogen water generated in the first electrode chamber (Da) by electrolysis to the outside; and an electric charge-adjusting device (10), which is connected to the electrolysis tank (D) and is for adjusting the electric charge applied on the electrolyzed hydrogen water when performing the electrolysis. The electric charge-adjusting device (10) is characterized in adjusting the electric charge per unit volume of electrolyzed hydrogen water taken from the device by controlling the electrolytic current or electrolytic voltage.

IPC Classes  ?

• C02F 1/46 - Treatment of water, waste water, or sewage by electrochemical methods
• A01G 31/00 - Soilless cultivation, e.g. hydroponics

Abstract

A living body pressing clip (1A) comprises a clip body (10) and a cylindrical member (20) that is slidably attached to the clip body (10) and fastens the clip body (10). The clip body (10) is provided with arm parts (11) that hold a mucosal tissue in a luminal organ when fastened by the cylindrical member (20). The cylindrical member (20) is provided with a pressing part (22) that presses the mucosa in a direction of thinning the thickness (D) of the mucosa in the state where the cylindrical member (20) fastens the clip body (10) so that the clip body (10) holds the mucosal tissue in the luminal organ. The pressing part (22) contains a fluorescent dye capable of emitting a red or near-infrared light when irradiated with an exciting light. By using this living body pressing clip (1A), a light-emitting site of a light-emitting marker attached to a mucosal tissue in a luminal organ can be confirmed with a good visibility, even in the case of observing from outside the luminal organ.

IPC Classes  ?

• A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

[Problem] To provide an artery visualization device capable of very appropriately visualizing a to-be-punctured artery and an artery imaging device used for the artery visualization device. [Solution] An artery visualization device (10) includes en irradiation unit (30) which irradiates the near-infrared light emitted from a light source (32) toward a back-side skin surface (22) at a visualization site (20) where a to-be-punctured artery (21) is running, a light guiding part (40) which encapsulates the light source and is pressed against the back-side skin surface and which is formed with a material of transmitting the near-infrared light emitted from the light source and suppressing reflection of the near-infrared light on the surface of the back-side skin surface, an optical filter (50) which blocks visible light and transmits the near-infrared light passing through a front-side skin surface (23) at the visualization site, a camera (60) (an imaging unit) which receives the near-infrared light passing through the optical filter to capture an image of the visualization site (20), and a monitor (70) (a display unit) which displays the image captured by the camera.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 90/13 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints guided by light, e.g. laser pointers
• A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
• A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced

Abstract

ABSTRACT Disclosed is resin compositions which, in selected embodiments, emit near infrared fluorescence with high quantum yield and which can be easily prepared, and a molded article thereof. The resin compositions, in selected embodiments, contain a near infrared fluorescent material; and a resin, in which the near infrared fluorescent material is one type or two or more types of compounds selected from the group consisting of compounds represented by General Formulas (13) to (14) R Rn RqB Rr Rk Rh413/N / Rs RI/ \Rm R (13) R Dfl Rq \m/ ,D, N Rk N N / R" RV \RmR (1a) and has a maximum fluorescence wavelength of 650 nm or longer. Date Recue/Date Received 2021-11-10

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08K 5/55 - Boron-containing compounds

Abstract

The present invention addresses the problem of providing an easily manufactured resin composition which exhibits near-infrared fluorescence and has high luminescence quantum yield, and a molded article thereof. The present invention is a resin composition containing a resin and a near-infrared fluorescent pigment comprising at least one type of compound selected from the group consisting of compounds represented by general formulas (I1)-(I4), the maximum fluorescence wavelength of the resin composition being at least 650 nm. (In the formulas, Ra and Rb, Rc and Rd, Rh and Ri, and Rj and Rk form rings together with a nitrogen atom to which each thereof is bonded; Re and Rf represent halogen atoms or oxygen atoms; Rl, Rm, Rn, and Ro each independently represents a halogen atom, a C1-20 alkyl group, a C1-20 alkoxy group, an aryl group, or a heteroaryl group; Rg, Rr, and Rs represent hydrogen atoms or electron-accepting groups; and Rp and Rq each independently represents a hydrogen atom, a halogen atom, a C1-20 alkyl group, a C1-20 alkoxy group, an aryl group, or a heteroaryl group.)

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08K 5/55 - Boron-containing compounds

Abstract

The issue addressed by the present invention is to easily provide: a resin composition with which detection by X-ray radiation, and detection by fluorescence or phosphorescence are possible; and a molded article obtained from said resin composition. The present invention is: a resin composition characterized by containing a light-emitting substance and a radiation-opaque substance; the resin composition, wherein the light-emitting substance is a near infrared fluorescent material or a phosphorescent material; a resin composition wherein the radiation-opaque substance is one of barium sulfate; bismuth oxide; bismuth subcarbonate, calcium carbonate, aluminum hydrate, tungsten, zinc oxide, zirconium oxide, zirconium, titanium, platinum, bismuth subnitrate, or bismuth; and a molded article obtained by processing one of the aforementioned resin compositions.

IPC Classes  ?

• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61L 29/00 - Materials for catheters or for coating catheters
• A61L 31/00 - Materials for other surgical articles
• C09K 11/00 - Luminescent, e.g. electroluminescent, chemiluminescent, materials
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

The issue addressed by the present invention is to easily provide: a resin composition with which detection by X-ray radiation, and detection by fluorescence or phosphorescence are possible; and a molded article obtained from said resin composition. The present invention is: a resin composition characterized by containing a light-emitting substance and a radiation-opaque substance; the resin composition, wherein the light-emitting substance is a near infrared fluorescent material or a phosphorescent material; a resin composition wherein the radiation-opaque substance is one of barium sulfate; bismuth oxide; bismuth subcarbonate, calcium carbonate, aluminum hydrate, tungsten, zinc oxide, zirconium oxide, zirconium, titanium, platinum, bismuth subnitrate, or bismuth; and a molded article obtained by processing one of the aforementioned resin compositions.

IPC Classes  ?

• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61L 29/00 - Materials for catheters or for coating catheters
• A61L 31/00 - Materials for other surgical articles
• C09K 11/00 - Luminescent, e.g. electroluminescent, chemiluminescent, materials
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

Disclosed is a device which can promote the in vivo production of acetylcholine. An in vivo acetylcholine production-promoting device is equipped with: an artery-compressing member which contacts with any site of four limbs and compresses an artery located at the site when the artery-compressing member is pressurized; and a pressurizing means which is connected to the artery-compressing member, pressurizes the artery-compressing member to compress the artery so that the flow of blood in the artery is interrupted during use and releases the pressurized state to re-perfuse blood through the artery. By applying the device to an animal body and repeating the interruption of blood flow and the reperfusion of blood in an artery in four limbs, the production of acetylcholine can be promoted and the concentration of acetylcholine in vivo can be increased.

IPC Classes  ?

• A61B 17/132 - Tourniquets

Abstract

[Problem] To accurately check a usage status of a medical product such as a damage status of the medical product or existence or nonexistence of the medical product. [Solution] A medical product (80) is configured to include a light-emissive septum (83) (constituent member) which includes a luminescent agent emitting near-infrared fluorescence according to irradiation of excitation light on a surface thereof. Even in a case where a portion of the septum is separated as a core (83a) (separate piece) due to damage, the luminescent agent is also included on a surface of the core. A medical product usage status checking apparatus (10) is configured to include a medical product which emits the near-infrared fluorescence, an irradiation unit (130) which irradiates the medical product with excitation light which excites the luminescent agent, an optical filter (140) which blocks the excitation light and transmits the near-infrared fluorescence emitted by the luminescent agent, a camera (15) (imaging unit) which receives the near-infrared fluorescence passing through the optical filter, and a monitor (160) (display unit) which displays an image captured by the camera. An image based on the near-infrared fluorescence of the septum is displayed on the monitor and in a case where damage occurs in the septum, an image based on the near-infrared fluorescence of the core is displayed on the monitor.

IPC Classes  ?

• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 90/90 - Identification means for patients or instruments, e.g. tags
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Provided are: an artery visualization device (10) that can suitably visualize an artery on which a puncture is to be performed; and an artery imaging device (60) used in said artery visualization device. The artery visualization device (10) has the following: an illumination unit (30) that shines near-infrared light, emitted by a light source (32), toward the rear skin surface (22) of a visualization site (20) through which the artery (21) to be punctured runs; a light-guiding part (40) that encapsulates the light source, is pressed against the rear skin surface, and is formed from a material that transmits the near-infrared light emitted from the light source but reduces reflection of the near-infrared light from the rear skin surface; an optical filter (50) that blocks visible light but transmits near-infrared light that has passed through the front skin surface (23) of the visualization site; a camera (60) that images the visualization site by receiving near-infrared light that has passed through the optical filter; and a monitor (70) that displays the image taken by the camera.

IPC Classes  ?

• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests

Abstract

[Problem] To make it possible to reliably ascertain the usage status of a medical product, e.g. the damage status of said medical product or the presence or absence of said medical product. [Solution] A medical product (80) is provided with a light-emission-capable septum (83) (constituent member), the surface of which contains a light-emitting agent that emits near-infrared fluorescence upon being illuminated with excitation light. Even if part of the septum detaches due to damage, forming a core (83a) (detached fragment), the surface of said core also contains the light-emitting agent. This medical-product usage-status ascertainment device (10) has the following: the aforementioned medical product that emits near-infrared fluorescence; an illumination unit (130) that shines, toward said medical product, excitation light that excites the light-emitting agent; an optical filter (140) that blocks the excitation light but transmits the near-infrared fluorescence emitted by the light-emitting agent; a camera (150) (imaging unit) that receives near-infrared fluorescence that has passed through the optical filter; and a monitor (160) (display unit) that displays images taken by the camera. The monitor displays an image based on near-infrared fluorescence from the septum, and if the septum has been damaged, displays an image based on near-infrared fluorescence from the core.

IPC Classes  ?

• A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)

Abstract

The invention provides a tumor antigen-specific Th-inducing polypeptide capable of efficient antigen presentation, and an antitumor agent using the same.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 37/08 - Antiallergic agents
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/77 - Ovalbumin
• C07K 14/82 - Translation products from oncogenes

Abstract

The purpose of the present invention is to provide a highly effective therapeutic agent for pancreatic cancer and/or biliary tract cancer. A therapeutic agent for pancreatic cancer and/or biliary tract cancer, comprising the following components (1) and (2) as essential components: (1) at least one branched amino acid selected from the group consisting of isoleucine, leucine and valine; and (2) gemcitabine or a salt thereof.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Problem] To provide a prophylactic agent and/or a treatment agent for side effects of cancer drugs. [Solution] This invention provides a prophylactic agent and/or a treatment agent for side effects of cancer drugs which contains ALA substances.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/28 - Compounds containing heavy metals
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 33/26 - IronCompounds thereof
• A61K 33/30 - ZincCompounds thereof
• A61P 7/06 - Antianaemics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• A61K 49/00 - Preparations for testing in vivo
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

Abstract

The medical tool position-confirming system is provided with: a luminescent medical tool (1) with a luminescent agent, which emits fluorescence as a result of being irradiating with near infrared light of 600 nm - 1400 nm wavelength, coated on or kneaded into the surface; a light source (3) that irradiates the near infrared light (2) towards the medical tool (1); a camera (4) that receives the near infrared fluorescence emitted by the luminescent agent of the medical tool (1); and a monitor (6) that projects the image (5) taken by the camera (4). The position of medical tools such as shunt tubes and the like can be confirmed without the use of X-rays.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61L 29/00 - Materials for catheters or for coating catheters
• A61L 31/00 - Materials for other surgical articles
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems

Abstract

Disclosed is a method for ditecting urothelial cancer in a simple manner and with high accuracy. Specifically disclosed is a method for detecting urothelial cancer, which comprises administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of the compound or the derivative to a subject, collecting urine from the subject, and determining the presence or amount of a fluorescence in a cell contained in the urine collected from the subject.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/493 - Physical analysis of biological material of liquid biological material urine
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

Provided is a fluorescent endoscopic device or the like that does not require an optical filter and does not require special image signal processing for the purpose of color correction. In the structure of the device equipped with an excitation light radiation means (1), a radiation means drive means (3), a photoelectric conversion means (8) that converts fluorescent light generated by living tissue into an electrical signal, a photoelectric conversion element drive means (6) that determines the drive timing for the photoelectric conversion means (8), and a stored charge reset means (6) that resets a charge stored in the photoelectric conversion means (8), the excitation light radiation means (1) is driven intermittently, and when the excitation light radiation means (1) is not being driven, the photoelectric conversion element drive means (6) drives the photoelectric conversion means (6) to perform photoelectric conversion.

IPC Classes  ?

• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• H04N 5/225 - Television cameras
• H04N 5/238 - Circuitry for compensating for variation in the brightness of the object by influencing optical part of the camera

Abstract

The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses.

IPC Classes  ?

• A61K 39/10 - BrucellaBordetella, e.g. Bordetella pertussis
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 39/02 - Bacterial antigens

Abstract

A mixture of fermented artemisia with ginger is used for promoting the growth of animals or humans and promoting body weight gain in animals and humans to thereby increase livestock raising earnings and keep humans in good health. The mixture of fermented artemisia with ginger is prepared by fermenting artemisia with the use of one or more kinds of fermenting microorganisms selected from among a lactic acid bacterium, a yeast, a photosynthetic bacterium, an actinomycete, a thermophilic batch, koji mold and Bacillus natto and adding the fermented artemisia liquor thus obtained to ginger. The mixture of fermented artemisia withginger is added in an amount of 0.5 to 2.0% by weight to a feed or a food. Thus, it becomes possible to promote the growth of animals or humans and promote body weight gain in animals and humans to thereby increase livestock raising earnings and keep humans in good health.

IPC Classes  ?

• A23K 1/16 - supplemented with accessory food factors; Salt blocks
• A23K 1/14 - from vegetable materials, e.g. potatoes or roots without ensilaging
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
• A61K 35/74 - Bacteria
• A61K 36/06 - Fungi, e.g. yeasts
• A61K 36/18 - Magnoliophyta (angiosperms)
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61P 3/02 - Nutrients, e.g. vitamins, minerals

Abstract

This invention provides a process for producing a fine-particle composite comprising a fine particle of a sulfide or a composite sulfide of one or more elements selected from molybdenum (Mo), rhodium (Rh), ruthenium (Ru), and rhenium (Re) and electroconductive fine particles. The production process comprises the step of preparing a solvent mixed liquid from an electroconductive carbon powder, one or more compounds containing an element selected from molybdenum (Mo), rhodium (Rh), ruthenium (Ru), and rhenium (Re), and a compound containing sulfur (S), and the step of subjecting the solvent mixed liquid to a hydrothermal reaction or a solvothermal reaction at a pressure and a temperature that bring water or the solvent to a supercritical state or a subcritical state.

IPC Classes  ?

• B01J 27/045 - Platinum group metals
• B01J 27/049 - Sulfides with chromium, molybdenum, tungsten or polonium with iron group metals or platinum group metals
• B01J 35/02 - Solids
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• C01G 39/06 - Sulfides
• C01G 47/00 - Compounds of rhenium
• C01G 55/00 - Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material
• H01M 4/96 - Carbon-based electrodes
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

This invention provides a fine particle composite comprising fine powder of a sulfide or sulfide complex comprising a given element. The fine particle composite is obtained by a method for producing a fine particle composite comprising fine powder of a sulfide or sulfide complex comprising at least one element selected from the group consisting of molybdenum (Mo), rhodium (Rh), ruthenium (Ru), and rhenium (Re). Such method comprises steps of: preparing a solvent mixture from at least one compound containing an element selected from among molybdenum (Mo), rhodium (Rh), ruthenium (Ru), rhenium (Re), and sulfur (S); and subjecting the solvent mixture to a hydrothermal or solvothermal reaction. The resulting fine particle composite comprises fine particles of a sulfide or sulfide complex comprising at least one element selected from the group consisting of molybdenum (Mo), rhodium (Rh), ruthenium (Ru), and rhenium (Re).

IPC Classes  ?

• C01G 39/06 - Sulfides
• C01G 47/00 - Compounds of rhenium
• C01G 55/00 - Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum

Abstract

As an agent which is less expensive, highly safe and effective for exterminating pathogenic bacteria in fishes, for example, pathogenic bacteria causing gliding bacterial disease in Seriola quinqueradiata, Pagrus major or Paralichthys olivaceus, fishes parasitized with pathogenic bacteria are treated with an agent comprising an organic acid as the main component. Thus, the pathogenic bacteria are safely and effectively controlled and exterminated.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof